Aptinyx
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The last earnings update was 33 days ago. More info.
Add to Portfolio Compare Print
- Aptinyx has significant price volatility in the past 3 months.
APTX Share Price and Events
7 Day Returns
1 Year Returns
APTX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Aptinyx (APTX) | -2.3% | -16% | -29.8% | - | - | - |
| US Biotechs | -0.6% | -0.9% | -9.1% | -8.8% | 11.6% | 4.7% |
| US Market | 0.5% | 0.2% | 1.1% | 0.8% | 37.4% | 37.5% |
1 Year Return vs Industry and Market
- No trading data on APTX.
- No trading data on APTX.
APTX Value
Is Aptinyx undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Aptinyx. This is due to cash flow or dividend data being unavailable. The share price is $2.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Aptinyx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Aptinyx's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-2.14 |
| NasdaqGS:APTX Share Price ** | NasdaqGS (2019-06-14) in USD | $2.95 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.23x |
| United States of America Market PE Ratio | Median Figure of 3,091 Publicly-Listed Companies | 17.68x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Aptinyx.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:APTX Share Price ÷ EPS (both in USD) = 2.95 ÷ -2.14 |
-1.38x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aptinyx is loss making, we can't compare its value to the US Biotechs industry average.
- Aptinyx is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Aptinyx's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.38x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
-18.2%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 1.08x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Aptinyx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Aptinyx's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $4.03 |
| NasdaqGS:APTX Share Price * | NasdaqGS (2019-06-14) in USD | $2.95 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 425 Publicly-Listed Biotechs Companies | 2.9x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:APTX Share Price ÷ Book Value per Share (both in USD) = 2.95 ÷ 4.03 |
0.73x |
* Primary Listing of Aptinyx.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aptinyx is good value based on assets compared to the US Biotechs industry average.
Value checks
We assess Aptinyx's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Aptinyx has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
APTX Future Performance
How is Aptinyx expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Aptinyx's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Aptinyx's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
- Aptinyx's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:APTX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | -18.2% |
| NasdaqGS:APTX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 5.7% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 18% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 5 | -107 | -144 | 3 |
| 2022-12-31 | 5 | -96 | -142 | 2 |
| 2021-12-31 | 5 | -90 | -150 | 2 |
| 2020-12-31 | 4 | -76 | -93 | 5 |
| 2019-12-31 | 4 | -66 | -79 | 5 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 5 | -52 | -58 |
| 2018-12-31 | 7 | -47 | -53 |
| 2018-09-30 | 7 | -41 | -46 |
| 2018-06-30 | 7 | -37 | -40 |
| 2018-03-31 | 6 | -35 | -35 |
| 2017-12-31 | 5 | -33 | -32 |
| 2016-12-31 | 10 | -20 | -15 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from Aptinyx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -2.43 | -2.43 | -2.43 | 1.00 |
| 2022-12-31 | -2.42 | -2.42 | -2.42 | 1.00 |
| 2021-12-31 | -2.94 | -2.94 | -2.94 | 1.00 |
| 2020-12-31 | -2.25 | -1.79 | -2.77 | 4.00 |
| 2019-12-31 | -2.24 | -2.09 | -2.50 | 4.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -2.14 |
| 2018-12-31 | -2.64 |
| 2018-09-30 | -3.52 |
| 2018-06-30 | -6.96 |
| 2018-03-31 | -6.65 |
| 2017-12-31 | -6.17 |
| 2016-12-31 | -3.16 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Aptinyx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Aptinyx's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Aptinyx has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
APTX Past Performance
How has Aptinyx performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Aptinyx does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- Unable to compare Aptinyx's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Aptinyx's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Aptinyx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 5.00 | -58.32 | 16.35 | |
| 2018-12-31 | 6.57 | -53.28 | 12.67 | |
| 2018-09-30 | 6.72 | -46.41 | 9.59 | |
| 2018-06-30 | 6.98 | -40.38 | 7.12 | |
| 2018-03-31 | 6.28 | -35.04 | 6.37 | |
| 2017-12-31 | 4.96 | -32.07 | 5.55 | |
| 2016-12-31 | 9.79 | -15.48 | 4.77 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Aptinyx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Aptinyx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Aptinyx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Aptinyx's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Aptinyx has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
APTX Health
How is Aptinyx's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Aptinyx's finances.
The net worth of a company is the difference between its assets and liabilities.
- Aptinyx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Aptinyx's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Aptinyx has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Aptinyx Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 134.69 | 0.00 | 136.58 |
| 2018-12-31 | 149.31 | 0.00 | 150.64 |
| 2018-09-30 | 161.97 | 0.00 | 165.58 |
| 2018-06-30 | 175.54 | 0.00 | 179.09 |
| 2018-03-31 | 81.52 | 0.00 | 82.35 |
| 2017-12-31 | 92.67 | 0.00 | 92.14 |
| 2016-12-31 | 14.10 | 0.00 | 16.18 |
- Aptinyx has no debt.
- Aptinyx has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Aptinyx has sufficient cash runway for 2.6 years based on current free cash flow.
- Aptinyx has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 35.8% each year.
Financial health checks
We assess Aptinyx's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Aptinyx has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
APTX Dividends
What is Aptinyx's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Aptinyx
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Aptinyx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Aptinyx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Aptinyx has not reported any payouts.
- Unable to verify if Aptinyx's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Aptinyx's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Aptinyx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Aptinyx has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
APTX Management
CEO
| COMPENSATION | $10,605,446 |
| AGE | 60 |
| TENURE AS CEO | 4 years |
CEO Bio
Dr. Norbert G. Riedel, Ph.D., serves as Board Member at TRACT Therapeutics, Inc. He serves as Chairman of Eton Pharmaceuticals, Inc. and serves as Industry Advisor at Agent Capital, LLC. He has been President, Chief Executive Officer and Director of Aptinyx Inc. since June 2015. He serves as a Senior Executive Advisor at Beecken Petty O'Keefe & Company. Dr. Riedel served as the Chief Executive Officer and President of Naurex, Inc. since January 1, 2014 to September 2015. Dr. Riedel served as the Chief Science & Innovation Officer and Corporate Vice President of Baxter International Inc., from May 2001 to 2013. He served as Senior Vice President of Baxter International Inc. From 1998 to March 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit of Baxter International Inc. He served as General Manager of the recombinant therapeutic proteins business at Baxter. Prior to joining Baxter in 1998, he served as the Head of worldwide/Global Biotechnology and Global Core Research Functions at Hoechst Marion Roussel Inc. (now Sanofi-Aventis) from 1996 to 1998. He served as the Chairman of the Board of Biotechnology Industry Organization since July 1, 2006. He served as Deputy Chairman of Supervisory Board at MediGene AG., until July 16, 2013. He has been an Independent Director of Jazz Pharmaceuticals Public Limited Company since May 2, 2013. He serves as a Member at Large of Illinois Biotechnology Industry Organization. He served as a Director of DuPont Industrial Biosciences (Danisco US Inc.) since November 2000. He has been a Director of Naurex, Inc since December 2012. He has been Director of Eton Pharmaceuticals, Inc. since September 7, 2017. He serves as a Director of Nanomateria Inc., Biotechnology Innovation Organization and iBIO Institute. He serves as a Member of the Advisory Board of Northwestern University's Kellogg School of Management Center for Biotechnology. Dr. Riedel is a member of the Austrian Academy of Sciences and Illinois Innovation Council. He served as a Member of Scientific Advisory Board of GlycoFi, Inc. He served as a Director of Ariad Pharmaceuticals, Inc. from April 28, 2011 to February 16, 2017. He served as a Member of the Supervisory Board at MediGene AG since October 27, 2003. He served as an Independent Director of Oscient Pharmaceuticals Corp. (formerly, Genome Therapeutics Corp.) since 1999. He served as an Assistant Professor and Associate Professor of Medicine and Biochemistry at Boston University School of Medicine from 1987 to 1991 and a Visiting Professor at Massachusetts Institute of Technology since 1992. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University’s Feinberg School of Medicine. He has a Diploma in Biochemistry from the University of Frankfurt in 1981. Dr. Riedel received his Ph.D. in Biochemistry from the University of Frankfurt in 1983. He was a Postdoctoral Fellow at Harvard University from 1984 to 1987.
CEO Compensation
- Norbert's compensation has increased whilst company is loss making.
- Norbert's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Aptinyx management team in years:
- The average tenure for the Aptinyx management team is less than 2 years, this suggests a new team.
Management Team
Norbert Riedel
President
$11M
60
4 yrs
Ashish Khanna
CFO & Chief Business Officer
$2M
42
1.3 yrs
Andy Kidd
Chief Operating Officer
$2M
42
0.3 yrs
Juan Estupinan
Vice President of Finance & Accounting and Controller
0.3 yrs
Joseph Moskal
Chief Scientific Officer
$498K
67
3.9 yrs
Patricia Adams
Vice President of Human Resources & Administration
0.3 yrs
Betty Jang
Vice President of Legal Affairs
49
0.5 yrs
Nick Smith
Director of Corporate Development
Kathryn King
Senior Vice President - Clinical Development
0.4 yrs
Board of Directors Tenure
Average tenure and age of the Aptinyx board of directors in years:
- The tenure for the Aptinyx board of directors is about average.
Board of Directors
Bill Gantz
Chairman of the Board
$38K
80
Norbert Riedel
President
$11M
60
4 yrs
Jamie Topper
Director
$23K
56
3.1 yrs
Adam Koppel
Director
$24K
48
1.5 yrs
Bob Hombach
Director
$218K
52
1.1 yrs
Patrick Enright
Director
$24K
57
3.1 yrs
Terry Gould
Director
$21K
61
3.9 yrs
Henry Gosebruch
Director
45
0.1 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Aptinyx insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 09. May 19 | Buy | Henry Gosebruch | Individual | 07. May 19 | 08. May 19 | 100,000 | $3.86 | $385,624 | ||
| 30. Jan 19 | Buy | Torsten Madsen | Individual | 28. Jan 19 | 28. Jan 19 | 1,050 | $5.27 | $5,534 | ||
| 28. Jan 19 | Buy | Robert Hombach | Individual | 24. Jan 19 | 25. Jan 19 | 25,000 | $5.54 | $138,233 | ||
| 19. Jan 19 | Buy | Ashish Khanna | Individual | 18. Jan 19 | 18. Jan 19 | 10,000 | $5.45 | $54,500 | ||
| 26. Jun 18 | Buy | Bain Capital, LP | Company | 25. Jun 18 | 25. Jun 18 | 400,000 | $16.00 | $6,400,000 | ||
| 26. Jun 18 | Buy | Frazier Healthcare Partners | Company | 25. Jun 18 | 25. Jun 18 | 150,000 | $16.00 | $2,400,000 | ||
| 26. Jun 18 | Buy | New Leaf Venture Partners, L.L.C. | Company | 25. Jun 18 | 25. Jun 18 | 250,000 | $16.00 | $4,000,000 | ||
| 26. Jun 18 | Buy | Adams Street Partners, LLC | Company | 25. Jun 18 | 25. Jun 18 | 150,000 | $16.00 | $2,400,000 | ||
| 26. Jun 18 | Buy | Longitude Capital Management Co., LLC | Company | 25. Jun 18 | 25. Jun 18 | 150,000 | $16.00 | $2,400,000 | ||
| 26. Jun 18 | Buy | Wilbur Gantz | Individual | 25. Jun 18 | 25. Jun 18 | 23,100 | $16.00 | $369,600 | ||
| 26. Jun 18 | Buy | Joseph Moskal | Individual | 25. Jun 18 | 25. Jun 18 | 3,000 | $16.00 | $48,000 | ||
| 26. Jun 18 | Buy | Torsten Madsen | Individual | 25. Jun 18 | 25. Jun 18 | 1,000 | $16.00 | $16,000 | ||
| 26. Jun 18 | Buy | Andrew Kidd | Individual | 25. Jun 18 | 25. Jun 18 | 6,700 | $16.00 | $107,200 | ||
| 26. Jun 18 | Buy | Ashish Khanna | Individual | 25. Jun 18 | 25. Jun 18 | 7,800 | $16.00 | $124,800 | ||
| 26. Jun 18 | Buy | Norbert Riedel | Individual | 25. Jun 18 | 25. Jun 18 | 2,400 | $16.00 | $38,400 | ||
| 26. Jun 18 | Buy | Robert Hombach | Individual | 25. Jun 18 | 25. Jun 18 | 24,100 | $16.00 | $385,600 | ||
Management checks
We assess Aptinyx's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Aptinyx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
APTX News
Simply Wall St News
Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares?
So shareholders might well want to know whether insiders have been buying or selling shares in Aptinyx Inc. … Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. … In the last twelve months Aptinyx insiders were buying shares, but not selling
Simply Wall St - – Full articleHow Many Insiders Bought Aptinyx Inc. (NASDAQ:APTX) Shares?
Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … (NASDAQ:APTX), you may well want to know whether insiders have been buying or selling. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'.
Simply Wall St - – Full articleDo Insiders Own Lots Of Shares In Aptinyx Inc. (NASDAQ:APTX)?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of US$678m, Aptinyx is a small cap stock, so it might not be well known by many institutional investors. … We can zoom in on the different ownership groups, to learn more about APTX
Simply Wall St - – Full articleAre Aptinyx Inc's (NASDAQ:APTX) Interest Costs Too High?
The direct benefit for Aptinyx Inc (NASDAQ:APTX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is APTX will have to adhere to stricter debt covenants and have less financial flexibility. … Is APTX right in choosing financial flexibility over lower cost of capital.
Simply Wall St - – Full articleHow Financially Strong Is Aptinyx Inc (NASDAQ:APTX)?
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does APTX's growth rate justify its decision for financial flexibility over lower cost of capital … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt.
Simply Wall St - – Full articleAPTX Company Info
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson’s disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Details
| Name: | Aptinyx Inc. |
| APTX | |
| Exchange: | NasdaqGS |
| Founded: | 2015 |
| $99,008,522 | |
| 33,562,211 | |
| Website: | http://www.aptinyx.com |
| Address: |
Aptinyx Inc. 909 Davis Street, Suite 600, Evanston, Illinois, 60201, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | APTX | Common Stock | Nasdaq Global Select | US | USD | 21. Jun 2018 | |
| NasdaqGS | APTX | COM | Nasdaq Global Select | US | USD | 16. Jun 2019 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/16 01:02 |
| End of day share price update: | 2019/06/14 00:00 |
| Last estimates confirmation: | 2019/05/28 |
| Last earnings filing: | 2019/05/14 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
